Guelten Oskay-Oezcelik

Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik et al. · Journal of Clinical Oncology · 2008 · 136 citations · Full text

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner et al. · The Lancet Oncology · 2018 · 108 citations

Oncology, Medicine, Metronomic Therapy +8

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Philipp Harter et al. · Journal of Clinical Oncology · 2010 · 103 citations · Full text

Brain metastases from epithelial ovarian cancer: overview and optimal management.

Klaus Pietzner, Guelten Oskay-Oezcelik, K. El Khalfaoui et al. · PubMed · 2009 · 40 citations

Neuro-oncology, Tumoral Pathology, Tumor Innervation +13

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

Dominique Koensgen, Dirk Stengel, Antje Belau et al. · Cancer Chemotherapy and Pharmacology · 2007 · 16 citations

Multicenter Noggo, Tumoral Pathology, Phase I/ii Study +7